Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Miltefosine in Cutaneous Mastocytosis
2006-006704-10Phase 2Completed
- Sponsor
- JADO Technologies GmbH
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of miltefosine in cutaneous mastocytosis (CM), systemic mastocytosis (SM) and Diffuse cutaneous mastocytosis (DCM) (3 arms), sponsored by JADO Technologies GmbH. Primary endpoints: Treatment response by composite Darier's sign score (miltefosine vs placebo) and Treatment response (miltefosine vs Dermoxinale). Started Jan 2007; status: completed.
02
Drugs
miltefosine
03
Conditions
cutaneous mastocytosis (CM)systemic mastocytosis (SM)Diffuse cutaneous mastocytosis (DCM)
Beyond the preview
Go deeper on 2006-006704-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006704-10.